hVIVO (LON:HVO) Trading 7.1% Higher – Here’s Why

hVIVO plc (LON:HVO)’s share price rose 7.1% during mid-day trading on Thursday . The company traded as high as GBX 13.50 ($0.17) and last traded at GBX 13.50 ($0.17). Approximately 1,485,919 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 3,282,514 shares. The stock had previously closed at GBX 12.60 ($0.16).

hVIVO Price Performance

The business’s 50-day moving average price is GBX 16.76 and its 200 day moving average price is GBX 21.44. The company has a market capitalization of £102.60 million, a P/E ratio of 5.98 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

Insider Buying and Selling at hVIVO

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.22), for a total value of £520,581.82 ($671,545.18). Insiders own 14.03% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.